Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-124718
Filing Date
2021-10-08
Accepted
2021-10-08 17:21:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2129654d1_defa14a.htm DEFA14A 21766
2 GRAPHIC tm2129654d1_defa14aimg001.jpg GRAPHIC 9989
  Complete submission text file 0001104659-21-124718.txt   36761
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

IRS No.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39788 | Film No.: 211316114
SIC: 2834 Pharmaceutical Preparations